Breast Cancer Clinical Trials

• (Ability to understand and willingness to sign a written informed consent document.

• Men and women age ≥ 18 yrs

• Confirmed presence of metastatic/advanced invasive lobular breast cancer and measurable disease per RECIST (version 1.1) or PERCIST

• Available archival tumor tissue

• Eastern Cooperative Oncology Group Performance Status ≤ 2

• Hematologic parameters defined as: Absolute neutrophil count (ANC) ≥ 1000 cells/mm3,Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8 g/dL.

• Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN, eGFR \>60 mL/min/1.73m\*2

• Anticipated life expectancy ≥ 3 months

• Able to remain motionless for up to 30-60 minutes per scan.